Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
Under the terms of a settlement and license agreement with Regeneron, Samsung Bioepis will be able to launch Opuviz in the U.S. in January 2027, according to a press release.
“As with ranibizumab biosimilars, aflibercept biosimilars have the potential to significantly improve accessibility and affordability for patients,” Thomas Newcomer, vice president and head of U.S. commercial operations at Samsung Bioepis, told Healio. “As demand for treatment continues to grow, biosimilars can help manage costs with confidence without compromising on clinical standards.”
Opuviz (aflibercept-yszy 2 mg,